Medication info
Erityb Tablet 10mg (Ezetimibe)

Erityb Tablet 10mg (Ezetimibe)

Prescription medicationTablet
Ingredient · strength
Ezetimibe›10mg / 1 tablet
Manufacturer / importer
Erisun Pharmaceutical Co., Ltd.
Appearance
White to off-white oblong tablets
Packaging
30 tablets/box [10 tablets/PTP X 3]
Approval status
Active

MFDS item code 202002955 · Approved 2020.04.24 · Insurance code 620500320

Summary

Main use
Improvement of hypercholesterolemia, mixed dyslipidemia, and homozygous sitosterolemia
Who uses it
Adults
Adult dosage
A standard cholesterol-lowering diet should be continued during treatment with this medicine. The recommended dose of this medicine is 10 mg once daily, with or without food. When coadministered with an HMG-CoA reductase inhibitor (in patients with primary hypercholesterolemia), start this medicine at the recommended initial dose of the HMG-CoA reductase inhibitor. If the patient is already receiving a high dose of an HMG-CoA reductase inhibitor, administer this medicine concomitantly while maintaining the dose of the HMG-CoA reductase inhibitor. When this medicine is coadministered with fenofibrate (in patients with mixed hyperlipidemia), administer it with fenofibrate 160mg once daily or 200mg once daily (see Precautions for Use, 4. General Precautions). Administration to patients with hepatic impairment No dose adjustment is necessary in patients with mild hepatic impairment; however, administration of this medicine is not recommended in patients with moderate to severe hepatic impairment (see Precautions for Use, 2. Patients Requiring Cautious Administration). Administration to patients with renal failure No dose adjustment is necessary in patients with renal failure. Administration to older adults No dose adjustment is necessary when administering this medicine to older adults. Concomitant administration with bile acid sequestrants Administer this medicine at least 2 hours before or at least 4 hours after administration of a bile acid sequestrant (see Precautions for Use, 5. Interactions).

Ingredients

Manufacturer
Erisun Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of hypercholesterolemia, mixed dyslipidemia, and homozygous sitosterolemia

  • Primary hypercholesterolemia
  • elevated total cholesterol
  • low-density lipoprotein cholesterol
  • apolipoprotein B
  • mixed hyperlipidemia
  • non-high-density lipoprotein cholesterol
  • homozygous familial hypercholesterolemia
  • homozygous familial sitosterolemia
  • elevated sitosterol
  • campesterol
  • increased risk of atherosclerotic vascular disease due to hypercholesterolemia
  • dyslipidemia
View approved original text

This drug is used to reduce cholesterol and other lipid levels in patients with primary hypercholesterolemia, homozygous familial hypercholesterolemia, and homozygous sitosterolemia. In particular, it helps to lower key lipid markers such as total cholesterol, low-density lipoprotein cholesterol (LDL-C), and apolipoprotein B (Apo B). It can be administered alone or together with other lipid-lowering agents in conjunction with dietary therapy, playing an important role in reducing cardiovascular disease risk associated with hyperlipidemia. Additionally, before using this drug, secondary causes such as diabetes or hypothyroidism should be excluded and appropriate tests conducted for safe and effective treatment. Overall, this drug is used to improve dyslipidemia and reduce the risk of cardiovascular disease.

Dosage and Administration

Adult dosage

A standard cholesterol-lowering diet should be continued during treatment with this medicine. The recommended dose of this medicine is 10 mg once daily, with or without food. When coadministered with an HMG-CoA reductase inhibitor (in patients with primary hypercholesterolemia), start this medicine at the recommended initial dose of the HMG-CoA reductase inhibitor. If the patient is already receiving a high dose of an HMG-CoA reductase inhibitor, administer this medicine concomitantly while maintaining the dose of the HMG-CoA reductase inhibitor. When this medicine is coadministered with fenofibrate (in patients with mixed hyperlipidemia), administer it with fenofibrate 160mg once daily or 200mg once daily (see Precautions for Use, 4. General Precautions). Administration to patients with hepatic impairment No dose adjustment is necessary in patients with mild hepatic impairment; however, administration of this medicine is not recommended in patients with moderate to severe hepatic impairment (see Precautions for Use, 2. Patients Requiring Cautious Administration). Administration to patients with renal failure No dose adjustment is necessary in patients with renal failure. Administration to older adults No dose adjustment is necessary when administering this medicine to older adults. Concomitant administration with bile acid sequestrants Administer this medicine at least 2 hours before or at least 4 hours after administration of a bile acid sequestrant (see Precautions for Use, 5. Interactions).

Precautions

This drug should not be used in patients with allergic reactions to its components. Patients with severely impaired liver function or persistently elevated liver enzyme levels without an apparent cause should not take this drug in conjunction with certain lipid-lowering agents. Women who are pregnant or breastfeeding are prohibited from taking this drug along with certain lipid-lowering agents, so they should consult a doctor before administration. The use of this drug is not recommended in patients with moderate to severe liver dysfunction, and careful judgement should be made. Symptoms such as headache, abdominal pain, and diarrhea may occur when using this drug, and in rare cases, side effects such as muscle pain or elevated liver enzyme levels may also occur. If muscle pain or weakness symptoms appear, notify a doctor immediately, and in severe cases, drug discontinuation may be necessary. Patients with severely impaired kidney function should also be cautious when using this drug, and dose adjustments may be needed. Drug interactions may occur when used in combination with other drugs, so all medications being taken should be informed to healthcare providers. Particularly, caution is required when used with cholestyramine, fenofibrate, cyclosporine, anticoagulants, etc. Women who are pregnant or may become pregnant should consult healthcare providers before administration of this drug, and caution is also needed if breastfeeding. In children, this drug is not recommended for those under 6 years of age, and can be administered from the age of 6 under a doctor's judgement. Elderly patients can generally use it safely, but some may be more sensitive to the drug, so caution is necessary. When storing the drug, keep it out of reach of children, and be careful not to transfer it to another container.

Side effects

Fatigue, abdominal pain, diarrhea, viral infection, pharyngitis, sinusitis, arthralgia, low back pain, cough, chest pain, dizziness, headache, constipation, bloating, nausea, elevated AST, elevated ALT, myalgia, myopathy, rhabdomyolysis, increased aminotransferase levels, gallbladder-related adverse reactions, cholelithiasis, cholecystitis, anaphylaxis, urticaria, rash, angioedema, thrombocytopenia, pancreatitis, sensory disturbance, depression, mucocutaneous syndrome, toxic epidermal necrolysis, eosinophilia, systemic symptoms accompanying drug reactions, erythema multiforme, drug-induced liver injury, chest discomfort, edema, asthenia, generalized edema, diabetic neuropathy, tremor, upper abdominal pain, vomiting, gastritis, dry mouth, epigastric discomfort, belching, gastrointestinal disturbance, gastroesophageal reflux disease, tongue disorders, palpitations, congestive heart failure, myocardial ischemia, flushing, sputum, rhinorrhea, limb pain, diabetes mellitus, hypoglycemia, anemia, splenomegaly, pruritus, upper respiratory tract infection, conjunctival injection, renal failure, abnormal liver function, increased serum creatinine, elevated blood pressure, increased blood urea, increased serum creatine phosphokinase, abnormal liver function tests, nausea

Not everyone experiences these, and they can vary from person to person.

Storage

This drug is sensitive to air and moisture, so it should be stored in its original sealed container. The storage temperature should be kept between 1 degrees and 30 degrees Celsius at room temperature.

Appearance and packaging

Appearance

White to off-white oblong tablets

Package unit

30 tablets/box [10 tablets/PTP X 3]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.